Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 8:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 5,570 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Otitis Media
Interventions
Amoxicillin-Clavulanate potassium
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
6 Months to 23 Months
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
55
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 32 more
Conditions
Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ, Extragonadal Germ Cell Tumor, Ovarian Cancer
Interventions
bleomycin sulfate, amifostine trihydrate, cisplatin, etoposide, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 14 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 74 more
Conditions
HIV Infections
Interventions
Sulfamethoxazole-Trimethoprim, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Colorectal Neoplasms
Interventions
MK-2206 + AZD6244
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
70
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hueytown, Alabama + 67 more
Conditions
Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer
Interventions
PCS6422 and capecitabine, Capecitabine
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Los Angeles, California • Oxnard, California • Miami, Florida + 9 more
Conditions
Advanced Metastatic Cancer, Advanced Prostate Cancer
Interventions
Nivolumab Monotherapy, Nivolumab and Ipilimumab and Combination for Metastatic Cancer, Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer, Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer
Biological
Lead sponsor
Parker Institute for Cancer Immunotherapy
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 3 more
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
Interventions
Afatinib, Pemigatinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 3 Interventional Results available

Cross-linking for Corneal Ulcers Treatment Trial

NCT02570321
Conditions
Corneal Ulcer, Infectious Keratitis, Bacterial Ulcer, Fungal Ulcer
Interventions
Corneal Cross-linking, Anti Fungal Drug
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
celecoxib, adjuvant therapy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
4
States / cities
Chicago, Illinois • Chapel Hill, North Carolina
Conditions
Alcoholism, Alcohol Dependence, Depression
Interventions
naltrexone (Revia), fluoxetine (Prozac)
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Lymphoma
Interventions
Drug: Carfilzomib, Vorinostat
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Rochester, New York • Richmond, Virginia
Conditions
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
Interventions
YL201, Atezolizumab
Drug
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Plantation, Florida • Louisville, Kentucky + 2 more
Conditions
Breast Cancer
Interventions
Ramucirumab (IMC-1121B), Eribulin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • Gilroy, California • Palm Springs, California + 49 more
Conditions
Peripheral Arterial Disease, Peripheral Vascular Diseases, Catheterization, Peripheral
Interventions
NVS Therapy
Combination Product
Lead sponsor
Alucent Biomedical
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Columbus, Ohio • Wynnewood, Pennsylvania • Kingsport, Tennessee
Completed Phase 1 Interventional Results available

Daylight Photodynamic Therapy for Actinic Keratosis

NCT03322293
Conditions
Actinic Keratoses
Interventions
Aminolevulinic Acid Topical 20% Topical Solution, BLU-U blue light phototherapy illuminator
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine and Cedazuridine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma, Lymphoma, Non-Hodgkin's
Interventions
cemsidomide, Dexamethasone Oral
Drug
Lead sponsor
C4 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more
Conditions
Lung Cancer, Non-Small Cell
Interventions
Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Newark, Delaware • Springfield, Illinois • Rochester, Minnesota + 5 more
Conditions
Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
INQOVI (decitabine and cedazuridine), Nivolumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Sarcoma
Interventions
epirubicin hydrochloride, ifosfamide, sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, hypofractionated radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
15 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Advanced Solid Tumors
Interventions
Gemcitabine, Docetaxel, Temozolomide, Cisplatin, Erlotinib, LY573636
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Denver, Colorado + 16 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive

NCT03984825
Conditions
HIV Infections
Interventions
GSK3640254, Portia
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas